Description and application of a novel glucagon-like peptide-1 (GLP-1) radioimmunoassay

B. Lelesz, G. Tóth, B. Peitl, C. Hegedus, L. Drimba, R. Sári, Z. Szilvássy, J. Németh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The gut hormone glucagon-like peptide-1 (GLP-1) is derived from the transcription product of the proglucagon gene in the intestinal L cells. The known physiological functions of this peptide include: increases insulin and decreases glucagon secretion from the pancreas, furthermore promotes insulin sensitivity. Our research group working on diabetes and obesity, considered that it is important to develop an own specific and sensitive GLP-1 radioimmunoassay (RIA) method. The antiserum (GLP3/7), sensitive to the C-terminal region of peptide was produced by the immunization of rabbits administering GLP-1(19-37)-bovine serum albumin antigen subcutaneously. To show the antibody attachment we used iodogen method labelled mono-125I-GLP-1(19-37). GLP-1(19-37) peptide was used as standard for the RIA determination in a range of 0-1000 fm/ml. Our new RIA method was applied in an insulin resistance animal model. In the experiment Sprague-Dawley rats were treated with olanzapine (per os) 5 mg/kg body weight once a day for four weeks. Finally, in a glucose uptake experiment blood glucose and plasma GLP-1 levels were measured. After ten measurements the D50 value of the calibration curves was 15.18 ± 2.02 fmol/ml. The detection limit of our method was 0.4 fmol/ml GLP-1. The cross-reactivity studies showed that the antiserum used in our RIA method has a limited cross-reactivity with other peptides with similar structure. The difference of fasting blood glucose and GLP-1 plasma levels between control and olanzapine-treated animals were not significant, while blood glucose concentration was increased GLP-1 plasma level was significantly decreased during glucose uptake.

Original languageEnglish
Pages (from-to)157-164
Number of pages8
JournalJournal of Radioanalytical and Nuclear Chemistry
Volume299
Issue number1
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Glucagon-Like Peptide 1
Peptides
Radioimmunoassay
olanzapine
Glucose
Blood Glucose
Insulin
Plasmas
Insulin Resistance
Immune Sera
Blood
Animals
Proglucagon
Glucagon-Like Peptides
Enteroendocrine Cells
Immunization
Level control
Transcription
Medical problems
Bovine Serum Albumin

Keywords

  • I
  • Glucagon-like peptide-1 (GLP-1)
  • HPLC purification
  • Iodination
  • Radioimmunoassay (RIA)

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Spectroscopy
  • Public Health, Environmental and Occupational Health
  • Pollution
  • Health, Toxicology and Mutagenesis
  • Nuclear Energy and Engineering
  • Analytical Chemistry

Cite this

Description and application of a novel glucagon-like peptide-1 (GLP-1) radioimmunoassay. / Lelesz, B.; Tóth, G.; Peitl, B.; Hegedus, C.; Drimba, L.; Sári, R.; Szilvássy, Z.; Németh, J.

In: Journal of Radioanalytical and Nuclear Chemistry, Vol. 299, No. 1, 01.2014, p. 157-164.

Research output: Contribution to journalArticle

@article{184bf389f0fb4d24a8d6ea26b1df93d0,
title = "Description and application of a novel glucagon-like peptide-1 (GLP-1) radioimmunoassay",
abstract = "The gut hormone glucagon-like peptide-1 (GLP-1) is derived from the transcription product of the proglucagon gene in the intestinal L cells. The known physiological functions of this peptide include: increases insulin and decreases glucagon secretion from the pancreas, furthermore promotes insulin sensitivity. Our research group working on diabetes and obesity, considered that it is important to develop an own specific and sensitive GLP-1 radioimmunoassay (RIA) method. The antiserum (GLP3/7), sensitive to the C-terminal region of peptide was produced by the immunization of rabbits administering GLP-1(19-37)-bovine serum albumin antigen subcutaneously. To show the antibody attachment we used iodogen method labelled mono-125I-GLP-1(19-37). GLP-1(19-37) peptide was used as standard for the RIA determination in a range of 0-1000 fm/ml. Our new RIA method was applied in an insulin resistance animal model. In the experiment Sprague-Dawley rats were treated with olanzapine (per os) 5 mg/kg body weight once a day for four weeks. Finally, in a glucose uptake experiment blood glucose and plasma GLP-1 levels were measured. After ten measurements the D50 value of the calibration curves was 15.18 ± 2.02 fmol/ml. The detection limit of our method was 0.4 fmol/ml GLP-1. The cross-reactivity studies showed that the antiserum used in our RIA method has a limited cross-reactivity with other peptides with similar structure. The difference of fasting blood glucose and GLP-1 plasma levels between control and olanzapine-treated animals were not significant, while blood glucose concentration was increased GLP-1 plasma level was significantly decreased during glucose uptake.",
keywords = "I, Glucagon-like peptide-1 (GLP-1), HPLC purification, Iodination, Radioimmunoassay (RIA)",
author = "B. Lelesz and G. T{\'o}th and B. Peitl and C. Hegedus and L. Drimba and R. S{\'a}ri and Z. Szilv{\'a}ssy and J. N{\'e}meth",
year = "2014",
month = "1",
doi = "10.1007/s10967-013-2751-0",
language = "English",
volume = "299",
pages = "157--164",
journal = "Journal of Radioanalytical and Nuclear Chemistry",
issn = "0022-4081",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Description and application of a novel glucagon-like peptide-1 (GLP-1) radioimmunoassay

AU - Lelesz, B.

AU - Tóth, G.

AU - Peitl, B.

AU - Hegedus, C.

AU - Drimba, L.

AU - Sári, R.

AU - Szilvássy, Z.

AU - Németh, J.

PY - 2014/1

Y1 - 2014/1

N2 - The gut hormone glucagon-like peptide-1 (GLP-1) is derived from the transcription product of the proglucagon gene in the intestinal L cells. The known physiological functions of this peptide include: increases insulin and decreases glucagon secretion from the pancreas, furthermore promotes insulin sensitivity. Our research group working on diabetes and obesity, considered that it is important to develop an own specific and sensitive GLP-1 radioimmunoassay (RIA) method. The antiserum (GLP3/7), sensitive to the C-terminal region of peptide was produced by the immunization of rabbits administering GLP-1(19-37)-bovine serum albumin antigen subcutaneously. To show the antibody attachment we used iodogen method labelled mono-125I-GLP-1(19-37). GLP-1(19-37) peptide was used as standard for the RIA determination in a range of 0-1000 fm/ml. Our new RIA method was applied in an insulin resistance animal model. In the experiment Sprague-Dawley rats were treated with olanzapine (per os) 5 mg/kg body weight once a day for four weeks. Finally, in a glucose uptake experiment blood glucose and plasma GLP-1 levels were measured. After ten measurements the D50 value of the calibration curves was 15.18 ± 2.02 fmol/ml. The detection limit of our method was 0.4 fmol/ml GLP-1. The cross-reactivity studies showed that the antiserum used in our RIA method has a limited cross-reactivity with other peptides with similar structure. The difference of fasting blood glucose and GLP-1 plasma levels between control and olanzapine-treated animals were not significant, while blood glucose concentration was increased GLP-1 plasma level was significantly decreased during glucose uptake.

AB - The gut hormone glucagon-like peptide-1 (GLP-1) is derived from the transcription product of the proglucagon gene in the intestinal L cells. The known physiological functions of this peptide include: increases insulin and decreases glucagon secretion from the pancreas, furthermore promotes insulin sensitivity. Our research group working on diabetes and obesity, considered that it is important to develop an own specific and sensitive GLP-1 radioimmunoassay (RIA) method. The antiserum (GLP3/7), sensitive to the C-terminal region of peptide was produced by the immunization of rabbits administering GLP-1(19-37)-bovine serum albumin antigen subcutaneously. To show the antibody attachment we used iodogen method labelled mono-125I-GLP-1(19-37). GLP-1(19-37) peptide was used as standard for the RIA determination in a range of 0-1000 fm/ml. Our new RIA method was applied in an insulin resistance animal model. In the experiment Sprague-Dawley rats were treated with olanzapine (per os) 5 mg/kg body weight once a day for four weeks. Finally, in a glucose uptake experiment blood glucose and plasma GLP-1 levels were measured. After ten measurements the D50 value of the calibration curves was 15.18 ± 2.02 fmol/ml. The detection limit of our method was 0.4 fmol/ml GLP-1. The cross-reactivity studies showed that the antiserum used in our RIA method has a limited cross-reactivity with other peptides with similar structure. The difference of fasting blood glucose and GLP-1 plasma levels between control and olanzapine-treated animals were not significant, while blood glucose concentration was increased GLP-1 plasma level was significantly decreased during glucose uptake.

KW - I

KW - Glucagon-like peptide-1 (GLP-1)

KW - HPLC purification

KW - Iodination

KW - Radioimmunoassay (RIA)

UR - http://www.scopus.com/inward/record.url?scp=84892764540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892764540&partnerID=8YFLogxK

U2 - 10.1007/s10967-013-2751-0

DO - 10.1007/s10967-013-2751-0

M3 - Article

VL - 299

SP - 157

EP - 164

JO - Journal of Radioanalytical and Nuclear Chemistry

JF - Journal of Radioanalytical and Nuclear Chemistry

SN - 0022-4081

IS - 1

ER -